INTRODUCTION {#s1}
============

Colorectal cancer is one of the most common malignancies worldwide \[[@R1]--[@R3]\]. In recent years, the incidence rates of colorectal cancer are rapidly increasing in Asia \[[@R3]--[@R6]\]. In China, there has been a two- to four-fold increase in the incidence of colorectal cancer since the 1980s \[[@R7]--[@R9]\]. Accumulating epidemiologic evidence indicated that increased body mass index (BMI) was associated with an elevated risk of developing colorectal cancer \[[@R10]--[@R19]\]. And, the unfavorable increasing trend of colorectal cancer is thought to be, at least partly, due to the steep rise in prevalence of obesity \[[@R9], [@R20]--[@R22]\]. Therefore, better understanding the effect of obesity on colorectal cancer may lead to more effective cancer prevention strategy. However, till now, few investigations are available on the effect of BMI on the prognosis of colorectal cancer, with limited publications showed conflicting results \[[@R23]--[@R30]\]. Recently, a novel research paradigm in human malignancy found that the host-tumor interactions were able to modify tumor cell malignant behavior in humanmalignancies including colorectal cancer \[[@R31], [@R32]\]. In the link between excess energy balance and colorectal cancer malignant behavior, PI3K/AKT signaling pathway was found to be involved in by interacting with BMI \[[@R33]--[@R35]\]. Thus, the activation or inhibition of PI3K/AKT signaling pathway might determine the manner of colorectal cancer carcinogenesis in patients with different energy balance status.

N-Myc downstream-regulated gene (NDRG) family is comprised of four members, named NDRG1, NDRG2, NDRG3 and NDRG4 respectively, which share 57%--65% amino acid sequence homology \[[@R36], [@R37]\]. NDRG4, as the latest identified member, was previously considered to be specifically expressed in brain and heart tissue \[[@R36], [@R38]--[@R40]\]. However, we have demonstrated that NDRG4 protein expression was significantly decreased from normal mucosa, chronic colitis, ulcerative colitis, atypical hyperplasia to colorectal cancer tissues. In addition, NDRG4 in colorectal cancer was negatively correlated with PI3K/AKT activity and can significantly inhibit PI3K/AKT activity in tumor cell. These data suggested a tumor suppressive role of NDRG4 in carcinogenesis and progression, by the attenuation of PI3K/AKT signaling pathway \[[@R41]\]. Therefore, it is of theoretical rationality to deduce that the malignant behavior of colorectal cancer cells expressing NDRG4 might be from a PI3K/AKT-BMI interaction independent manner, whereas the malignant transformation of those with absent NDRG4 expression might be influenced by PI3K/AKT-BMI interaction. Considering the role of NDRG4 in the potential link with energy balance by PI3K/AKT attenuation, we hypothesized that activation of PI3K/AKT by absent NDRG4 expression might confer proliferative and progressive ability to colorectal cancer cells under excess energy balance status. Threrfore, it is possibile that the prognostic value of obesity in colorectal cancer might differ according to NDRG4 status.

To test this hypothesis, we investigated whether the associations of obesity with prognosis of colorectal cancer would be modified according to NDRG4 expression status in the present study.

RESULTS {#s2}
=======

Clinical and molecular characteristics of patients and specimens {#s2_1}
----------------------------------------------------------------

In the study cohort consisted of 226 colorectal cancer patients, the mean age was 58.2 years, with a range of 21 to 81. According to our predetermined BMI categories (described in Materials and Methods), 52 (23.0%) were obese, 85 (37.6%) patients were overweight, 89 (39.4%) were normal weight. The 10-gene panel test found that 36 (16.0%) tumors were MSI-H while 190 (84.1%) were MSS. Mutated KRAS, BRAF and PIK3CA was found in 78 (34.5%), 37 (16.4%) and 33 (14.6%) tumors, while wild type of KRAS, BRAF and PIK3CA was found in 148 (65.5%), 189 (83.6%) and 193 (85.4%) tumors, respectively. Clinical characteristics were showed in Table [1](#T1){ref-type="table"}.

###### Statistical results of NDRG4 expression

  Variable                     *n*   NDRG4 mRNA expression   *P*          
  ---------------------------- ----- ----------------------- ------------ ----------------------------------------------
  Total                        226   160 (70.8%)             66 (29.2%)   
  **Sex**                                                                 0.356[\*](#tfn_001){ref-type="table-fn"}
  Male                         187   130 (69.5%)             57 (30.5%)   
  Female                       39    30 (76.9%)              9 (23.1%)    
  **Age at diagnosis**                                                    0.855[\*](#tfn_001){ref-type="table-fn"}
  ≤ 60                         128   90 (70.3%)              38 (29.7%)   
  \> 60                        98    70 (71.4%)              28 (28.6%)   
  **BMI**                                                                 
  Normal weight                89    63 (70.8%)              26 (29.2%)   0.782[\*](#tfn_001){ref-type="table-fn"}
  Over weight                  85    62 (72.9%)              23 (27.1%)   
  Obese                        52    35 (67.3%)              17 (32.7%)   
  **Tumor location**                                                      0.824[\*](#tfn_001){ref-type="table-fn"}
  Right                        66    45 (68.2%)              21 (31.8%)   
  Left                         74    54 (73.0%)              20 (27.0%)   
  Rectum                       86    61 (70.9%)              25 (29.1%)   
  **Tumor size**                                                          0.783[\*](#tfn_001){ref-type="table-fn"}
  ≤ 3.0 cm                     42    29 (69.0%)              13 (31.0%)   
  \> 3.0 cm                    184   131 (71.2%)             53 (28.8%)   
  **Differentiation status**                                              \< 0.001[\*](#tfn_001){ref-type="table-fn"}
  Well                         46    24 (52.2%)              22 (47.8%)   
  Moderately                   99    67 (67.7%)              32 (32.3%)   
  Poor                         81    69 (85.2%)              12 (14.8%)   
  **Depth of invasion**                                                   \< 0.001[\*](#tfn_001){ref-type="table-fn"}
  T~1~ + T~2~                  77    32 (41.6%)              45 (58.4%)   
  T~3~ + T~4~                  149   128 (85.9%)             21 (14.1%)   
  **Vascular invasion**                                                   0.173[^†^](#tfn_002){ref-type="table-fn"}
  Absent                       216   151 (69.9%)             65 (30.1%)   
  Present                      10    9 (90.0%)               1 (10.0%)    
  **Lymph node metastasis**                                               \< 0.001[\*](#tfn_001){ref-type="table-fn"}
  Absent (N0)                  97    52 (53.6%)              45 (46.4%)   
  Present (N1--3)              129   108 (83.7%)             21 (16.3%)   
  **Distant metastasis**                                                  0.018[^†^](#tfn_002){ref-type="table-fn"}
  Absent (M0)                  202   138 (68.3%)             64 (31.7%)   
  Present (M1)                 24    22 (91.7%)              2 (8.3%)     
  **TNM stage**                                                           \< 0.001[^†^](#tfn_002){ref-type="table-fn"}
  I                            56    28 (50.0%)              28 (50.0%)   
  II                           41    23 (56.1%)              18 (43.9%)   
  III                          105   87 (82.9%)              18 (17.1%)   
  IV                           24    22 (91.7%)              2 (8.3%)     
  **MSI**                                                                 0.164[\*](#tfn_001){ref-type="table-fn"}
  MSS                          190   138 (72.6%)             52 (27.4%)   
  MSI-H                        36    22 (61.1%)              14 (38.9%)   
  **KRAS mutation**                                                       0.811[\*](#tfn_001){ref-type="table-fn"}
  (−)                          148   104 (70.3%)             44 (29.7%)   
  (+)                          78    56 (71.8%)              22 (28.2%)   
  **BRAF mutation**                                                       0.387[\*](#tfn_001){ref-type="table-fn"}
  (−)                          189   136 (72.0%)             53 (28.0%)   
  (+)                          37    24 (64.9%)              13 (25.1%)   
  **PIK3CA mutation**                                                     0.881[\*](#tfn_001){ref-type="table-fn"}
  (−)                          193   137 (71.0%)             56 (29.0%)   
  (+)                          33    23 (69.7%)              10 (30.3%)   

*P* value when expression levels were compared using Pearson *χ*^2^ test

*P* value when expression levels were compared using Fisher\'s exact test

NDRG4 mRNA expression and its association with clinicopathologic characteristics of patients {#s2_2}
--------------------------------------------------------------------------------------------

As normalized to 18s rRNA, the RQ (standing for relative expression obtained by 2^−ΔΔCt^ method) of NDRG4 mRNA in colorectal cancer samples was 1.12 ± 0.15 (mean ± SD), while the relative NDRG4 mRNA expression detected in matched adjacent normal tissues was 1.87 ± 0.21. NDRG4 mRNA expression in colorectal cancer was significantly decreased compared with that in adjacent normal specimens and noncancerous control mucosa samples (*P* \< 0.001). Based on the relative expression of NDRG4, we manually defined that the relative NDRG4 expression of 1.87 ± 0.21, which detected in adjacent normal tissues, as normal expression level of NDRG4 in colon mucosa, thus classified cancerous tissues into three groups: reduced expression of NDRG4 (less than 1.66), normal expression (1.66--2.08) and increased expression (over 2.08). For modeling purposes (because the number of tissues classified as increased expression of NDRG4 was small), cancerous tissues with normal and increased expression of NDRG4 were combined into a single group defined as having preserved NDRG4 expression. Therefore, 160 cases of colorectal cancer were defined as reduced NDRG4 expression group while 66 cases were defined as preserved expression group.

The correlation of NDRG4 mRNA levels with different clinicopathologic factors was shown in Table [1](#T1){ref-type="table"}. NDRG4 mRNA expression was found to be associated with tumor cell differentiation, depth of wall invasion, vascular invasion, lymph node metastasis, distant metastases and TNM stage since reduced NDRG4 expression was more frequently to be detected in tumors with poor differentiation (*P* \< 0.001), deep invasion (*P* \< 0.001), lymph node metastasis (*P* \< 0.001), distant metastases (*P* = 0.018) or advanced TNM stage (*P* \< 0.001). While no statistically significant correlations were observed between NDRG4 mRNA expression and sex (*P* = 0.356), age at diagnosis (*P* = 0.855), BMI (*P* = 0.782), tumor location (*P* = 0.824), tumor size (*P* = 0.783), KRAS mutation (*P* = 0.811), BRAF mutation (*P* = 0.387), PIK3CA mutation (*P* = 0.881) or MSI (*P* = 0.164).

NDRG4 stratifies the association of obesity with disease-free survival {#s2_3}
----------------------------------------------------------------------

Kaplan-Meier analysis was used to evaluate the disease-free survival of patients with colorectal cancer and NDRG4 mRNA expression. Results showed that patients with preserved NDRG4 expression in colorectal cancer tissues had better disease-free survival in comparison to those with reduced NDRG4 expression (Figure [1A](#F1){ref-type="fig"}, log-rank test: *P* \< 0.001), indicating that patients with colorectal cancer of reduced NDRG4 expression had a higher risk of tumor relapse compared with colorectal cancer of preserved NDRG4 expression. In addition, obesity (log-rank test: *P* = 0.032), tumor differentiation status (log-rank test: *P* \< 0.001), lymph node metastasis (log-rank test: *P* \< 0.001) and TNM stage (log-rank test: *P* \< 0.001), MSI(log-rank test: *P* \< 0.001), KRAS (log-rank test: *P* = 0.005), BRAF (log-rank test: *P* \< 0.001) and PIK3CA(log-rank test: *P* \< 0.001) mutations were also proved to be associated with disease-free survival of patients with colorectal cancer, which indicated that patients with obesity or patients with colorectal cancer of poor differentiation, advanced TNM stage, MSI, KRAS, BRAF or PIK3CA mutations had shorter disease-free survival and higher risk of relapse than those without. However, sex, age, tumor location, tumor size or vascular invasion had no prognostic value on disease-free survival of patients with colorectal cancer. Unadjusted hazard ratio (HR) was shown in Table [2](#T2){ref-type="table"}. To verify the independent prognostic value of NDRG4 mRNA expression on disease-free survival of patients with colorectal cancer, cox proportional hazards model adjusted for sex, age, tumor location, tumor size, differentiation status, vascular invasion, TNM stage, KRAS, BRAF and PIK3CA mutations and MSI status was utilized to control for other prognostic factors. As a result, NDRG4 mRNA expression level was proved to be an independent prognostic factor after controlling for all other clinicopathologic factors. Adjusted HR was 1.00 (as a reference) in NDRG4 preserved expression patients, the adjusted HR of patients with colorectal cancer of reduced NDRG4 expression was 1.65 (95% CI: 1.18--2.30 *P* = 0.003, Table [2](#T2){ref-type="table"}).

![**(A)** Kaplan-Meier analysis on the association of NDRG4 mRNA expression with disease-free survival of all recruited patients; **(B)** Kaplan-Meier analysis on the association of obesity with disease-free survival in patients with tumor of reduced NDRG4 expression.](oncotarget-07-1311-g001){#F1}

###### Association of NDRG4 and clinical factors with disease-free survival of patients with CRC

                           Unadjusted HR[^\*^](#tfn_003){ref-type="table-fn"}(95% CI)   *P*        Adjusted HR[^†^](#tfn_004){ref-type="table-fn"}(95% CI)   *P*
  ------------------------ ------------------------------------------------------------ ---------- --------------------------------------------------------- -------
  NDRG4 expression         1.98 (1.41--2.76)                                            \< 0.001   1.65 (1.18--2.30)                                         0.003
  Sex                      0.84 (0.57--1.26)                                            0.405      0.92 (0.64--1.45)                                         0.627
  Age at diagnosis         1.12 (0.82--1.54)                                            0.468      1.05 (0.77--1.51)                                         0.793
  Tumor location           1.25 (0.82--1.73)                                            0.763      1.03 (0.65--1.69)                                         0.902
  Tumor size               1.53 (0.98--2.39)                                            0.061      1.26 (0.59--2.71)                                         0.511
  Differentiation status   1.84 (1.17--2.90)                                            0.008      1.09 (0.65--1.94)                                         0.684
  Vascular invasion        1.78 (0.91--3.51)                                            0.094      0.61 (0.29--1.34)                                         0.173
  TNM stage                5.10 (2.79--9.33)                                            \< 0.001   3.68 (1.53--8.92)                                         0.003
  MSI                      1.88 (1.36--2.59)                                            \< 0.001   1.58 (1.11--2.24)                                         0.011
  KRAS mutation            1.56 (1.14--2.14)                                            0.006      1.46 (1.04--2.04)                                         0.028
  BRAF mutation            1.75 (1.28--2.39)                                            \< 0.001   1.56 (1.12--2.16)                                         0.008
  PIK3CA mutation          1.82 (1.31--2.52)                                            \< 0.001   1.65 (1.17--2.33)                                         0.004

Hazard ratios in univariate models

Hazard ratios in multivariable models

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.

We have previously demonstrated that NDRG4 can significantly inhibit PI3K-AKT activity which has been considered to be involved in the pathogenetic link between excess energy balance and cancer \[[@R33]\]. Thus, considering the potential significant interaction between NDRG4 and obesity of patients with colorectal cancer, we examined the association of obesity with disease-free in strata of NDRG4 expression. Interestingly, we found that, among tumors with NDRG4 reduced expression, obesity was associated with significantly worse overall survival (Figure [1B](#F1){ref-type="fig"}, log-rank test: *P* = 0.017), with unadjusted HR to be 1.65 (95% CI: 1.09--2.51 *P* = 0.018). While obesity was not found to be significantly associated with disease-free in NDRG4 preserved group (Table [3](#T3){ref-type="table"}). In multivariate analysis adjusted for sex, age, tumor location, tumor size, differentiation status, vascular invasion, TNM stage, KRAS, BRAF and PIK3CA mutations and MSI stutus, the association of disease-free survival with obesity was statistically significant for the adjusted HR was 1.71 (95% CI: 1.10--2.68 *P* = 0.018). These results indicated that obese patients with tumor of reduced NDRG4 expression, not preserved NDRG4 expression, had higher risk of tumor relapse compared with those nonobese patients.

###### Association of obesity with disease-free survival according to NDRG4 level

                                        Unadjusted HR[\*](#tfn_005){ref-type="table-fn"}(95% CI)   *P*     Adjusted HR[^†^](#tfn_006){ref-type="table-fn"}(95% CI)   *P*
  ------------------------------------- ---------------------------------------------------------- ------- --------------------------------------------------------- -------
  Obese vs Nonobese (NDRG4 reduced)     1.65 (1.09--2.51)                                          0.018   1.71 (1.10--2.68)                                         0.018
  Obese vs Nonobese (NDRG4 preserved)   1.47 (0.89--2.43)                                          0.131   1.45 (0.87--2.42)                                         0.156

Hazard ratios in univariate models

Hazard ratios in multivariable models

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.

NDRG4 stratifies the association of obesity with overall survival {#s2_4}
-----------------------------------------------------------------

A statistically significant association between poor overall survival and reduced NDRG4 mRNA expression level was found in patients with colorectal cancer. Kaplan-Meier analysis for postoperative overall survival showed that patients with colorectal cancer of preserved NDRG4 expression had longer overall survival compared with patients with reduced expression of NDRG4 (Figure [2A](#F2){ref-type="fig"}, log-rank test: *P* \< 0.001). Similar to results on disease-free survival, obesity (log-rank test: *P* = 0.036), tumor differentiation status (log-rank test: *P* \< 0.001), lymph node metastasis (log-rank test: *P* \< 0.001), TNM stage (log-rank test: *P* \< 0.001), MSI(log-rank test: *P* \< 0.001), KRAS(log-rank test: *P* = 0.014), BRAF(log-rank test: *P* = 0.003) and PIK3CA(log-rank test: *P* = 0.001) mutations were also proved to be prognostic factors for overall survival of patients with colorectal cancer. Patients with obesity and patients with colorectal cancer of poor differentiation, lymph node metastasis, advanced TNM stage, MSI, KRAS, BRAF or PIK3CA mutations had shorter overall survival. However, sex, age, tumor location, tumor size, vascular invasion or depth of invasion had no prognostic value on overall survival of patients with colorectal cancer. Unadjusted HR was shown in Table [4](#T4){ref-type="table"}. Multivariate analysis showed that NDRG4 could be a prognostic factor for overall survival of patients with colorectal cancer independent of gender, age, differentiation status, TNM stage, KRAS, BRAF and PIK3CA mutations and MSI status. The adjusted HR of patients with colorectal cancer of reduced NDRG4 expression was 1.64 (95% CI: 1.13--2.36 *P* = 0.008, Table [4](#T4){ref-type="table"}) with patients of preserved expression of NDRG4 to be reference. However, no statistically significant correlation between age, gender, tumor location, tumor size, vascular invasion or differentiation status and overall survival was found among patients with colorectal cancer.

![**(A)** Kaplan-Meier analysis on the association of NDRG4 mRNA expression with overall survival of all recruited patients; **(B)** Kaplan-Meier analysis on the association of obesity with overall survival in patients with tumor of reduced NDRG4 expression.](oncotarget-07-1311-g002){#F2}

###### Association of NDRG4 and clinical factors with overall survival of patients with CRC

                           Unadjusted HR[\*](#tfn_007){ref-type="table-fn"} (95% CI)   *P*        Adjusted HR[^†^](#tfn_008){ref-type="table-fn"}(95% CI)   *P*
  ------------------------ ----------------------------------------------------------- ---------- --------------------------------------------------------- -------
  NDRG4 expression         2.05 (1.46--2.98)                                           \< 0.001   1.64 (1.13--2.36)                                         0.008
  Sex                      0.73 (0.49--1.09)                                           0.128      0.83 (0.54--1.31)                                         0.391
  Age at diagnosis         1.12 (0.81--1.57)                                           0.490      1.12 (0.79--1.58)                                         0.488
  Tumor location           1.29 (0.86--1.96)                                           0.423      1.18 (0.69--2.04)                                         0.581
  Tumor size               1.69 (0.83--3.72)                                           0.056      1.63 (0.75--3.58)                                         0.231
  Differentiation status   2.33 (1.40--3.87)                                           0.001      1.25 (0.72--2.31)                                         0.453
  Vascular invasion        1.91 (0.97--3.77)                                           0.061      0.67 (0.31--1.48)                                         0.265
  TNM stage                5.76 (3.06--10.83)                                          \< 0.001   3.91 (1.58--9.75)                                         0.003
  MSI                      1.90 (1.35--2.68)                                           \< 0.001   1.57 (1.08--2.27)                                         0.018
  KRAS mutation            1.51 (1.08--2.11)                                           0.016      1.44 (1.01--2.07)                                         0.045
  BRAF mutation            1.65 (1.18--2.30)                                           0.003      1.49 (1.05--2.11)                                         0.026
  PIK3CA mutation          1.83 (1.29--2.59)                                           0.001      1.64 (1.13--2.36)                                         0.008

Hazard ratios in univariate models

Hazard ratios in multivariable models

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.

As investigation on disease-free survival demonstrated that in only reduced NDRG4 group, not preserved NDRG4 group, obese patients with colorectal cancer had higher risk of tumor relapse compared with those nonobese patients. In order to further test our hypothesis that activation of PI3K/AKT by absent NDRG4 expression might confer proliferative and progressive ability to colorectal cancer cells under excess energy balance status, which would impact the prognostic value of obesity, we next evaluated the association of obesity with overall survival according to NDRG4 level. Univariate survival analysis showed that obese patients with colorectal cancer of reduced NDRG4 expression had unfavorable overall survival compared with nonobese patients (Figure [2B](#F2){ref-type="fig"}, log-rank test: *P* = 0.020). In contrast, those obese patients with tumors of preserved NDRG4 expression were not found to have significantly diverse survival pattern from nonobese patients (Table [5](#T5){ref-type="table"}). In multivariate analysis, among patients with tumor of reduced NDRG4 expression, obesity was found to be independently associated with increased risk of death, with adjusted HR to be 1.67 (95% CI: 1.07--2.60, *P* = 0.023).

###### Association of obesity with overall survival according to NDRG4 level

                                        Unadjusted HR[\*](#tfn_009){ref-type="table-fn"} (95% CI)   *P*     Adjusted HR[^†^](#tfn_010){ref-type="table-fn"}(95% CI)   *P*
  ------------------------------------- ----------------------------------------------------------- ------- --------------------------------------------------------- -------
  Obese vs Nonobese (NDRG4 reduced)     1.66 (1.06--2.58)                                           0.028   1.67 (1.07--2.60)                                         0.023
  Obese vs Nonobese (NDRG4 preserved)   1.65 (0.96--2.84)                                           0.070   1.35 (0.75--2.42)                                         0.320

Hazard ratios in univariate models

Hazard ratios in multivariable models

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.

DISCUSSION {#s3}
==========

The biological function of NDRG4 is largely unknown in colorectal cancer until now. We have recently demonstrated that NDRG4 protein expression was significantly decreased during carcinogenesis process of colorectal cancer. And the activity of PI3K/AKT signaling in colorectal cancer can be effectly attenuated by NDRG4 \[[@R41]\]. Considering the significant role of PI3K/AKT signaling in carcinogenesis and energy metabolism, we tested the hypothesis that NDRG4 expression levle in colorectal cancer might correlate to patient\'s energy metabolism and modify tumor cell malignant behavior in the present study. As a result, we found that reduced NDRG4 mRNA expression was associated with tumor progression, as well as unfavorable outcome independent of patients\' clinical features and molecular variables including KRAS, BRAF and PIK3CA mutations and MSI status. These results were consistent with our previous invstigation on protein expression level of NDRG4 and further confirmed the tumor suppressor role of NDRG4 in colorectal cancer \[[@R41]\]. Although NDRG4 shares about 60% amino acid sequence homology with NDRG2, different from the widely tumor suppressive role of NDRG2, NDRG4 has been considered to be expressed mainly in brain and heart, and take part in the development of these organs. Until recently, investigations found that NDRG4 was overexpressed in human brain glioma and might promote tumor progression, indicating an oncogenetic role of NDRG4, which was opposed to the role of NDRG2 in human brain malignancy \[[@R42], [@R43]\]. However, we found that NDRG2 and NDRG4 mRNA expression was both decreased in colorectal cancer and adversely associated with clinical outcome within the same study cohort, indicating a tumor suppressive role of NDRG4 in colorectal cancer, which was similar to the role of NDRG2 in colorectal cancer \[[@R44]\]. These results suggested that NDRG4 and NDRG2 might both play tumor suppressive roles in colorectal cancer, which was different from their distinct roles in glioma. A recent comparative study on multitarget stool DNA test for colorectal cancer screening also showed that aberrant NDRG4 methylation was more likely to be detected in cancers, which further surport our results on the tumor suppressive role of NDRG4 in colorectal cancer \[[@R45]\].

Moreover, our investigation revealed that the prognostic impact of obesity on colorectal cancer relapse and overall mortility was significantly stratified by NDRG4 mRNA expression level. Specifically, among patients with tumor of reduce NDRG4 expression, obesity as associated with unfavorable disease-free and overall survival in both univariate and multivariate analysis. In contrast, no significant association of obesity with outcome was detected among patients with colorectal cancer of preserved NDRG4 expression. These results demonstrated that the adverse impact of obesity on colorectal cancer relapse and mortility was limited to patients with tumor of reduced NDRG4 expression, indicating that NDRG4 might correlate to patients\' carcinogenesis and energy metabolism in determination of colorectal cancer clinical outcome.

Investigation on molecular alterations and clinical prognostic factors would provide potential effective solution for colorectal cancer management \[[@R44], [@R46]--[@R51]\]. In human malignancy, inactivation of tumor suppressor gene or activation of oncogene is thought to imply aggressive tumor behavior. However, human colorectal cancer has been found to develop through accumulation of multiple genetic alternations and epigenetic events. Therefore, in order to acquire malignant or aggressive features, tumors with preserved NDRG4 expression may have to acquire other aberrations which would confer even more malignant or aggressive biological behavior than those with reduced NDRG4 expression does. In the present study, we found a significant stratifying impact of NDRG4 on the association between obesity and clinical outcome in colorectal cancer. As NDRG4 has been demonstrated to significantly inhibit PI3K/AKT activity, energy balance may be correlated to malignant behavior of tumors with reduced NDRG4 expression. The modifying effect of NDRG4 of the prognostic value of obesity indicated that excess energy balance might be detrimental among patients with tumors of NDRG4 reduced expression, probably due to the activation of PI3K/AKT signaling pathway by absence of NDRG4. These results provided evidences for a possible interactive effect of NDRG4 in colorectal cancer and patient\'s energy balance status in determining tumor cell behavior. Therefore, our data support the hypothesis that tumor cells with reduced NDRG4 expression my depend on the interaction between PI3K/AKT activation and excess energy balance for malignant transformation and further progression, whereas those with preserved NDRG4 expression might undergo carcinogenesis and progression independent of this kind of host-tumor interaction. Although these data need to be confirmed by further investigation, our intriguing results would contribute to understanding the exact role of obesity in outcome of colorectal cancer and may have considerable clinical implications.

Our study has several strengths. It included a hospital-based prospective study cohort to explore the expression pattern of NDRG4 mRNA and its association with disease-free and overall survival. The hospital-based cohort facilitated us to acquire disease-free and overall survival information exactly. The sample size of the present study was large and homogeneous, with adequate follow-up time and intimate information on clinicopathological characteristics. To avoid mRNA expression being altered by preoperative neoadjuvant therapy, we limited the cohort to patients who were diagnosed before the year 2006, before neoadjuvant therapy were routinely used for colorectal cancer in our department. In addition, we also investigated critical molecular events such as KRAS, BRAF and PIK3CA mutations and MSI status, all of which have been associated with colorectal cancer prognosis in order to adjusted our results \[[@R52]--[@R54]\].

In summary, our large cohort propective study demonstrated that mRNA expression levels of NDRG4 in primary colorectal cancer might be a powerful, independent predictor of disease relapse and prognosis. Our results also provided the first evidence that NDRG4 had significant modifying effect on the prognostic value of obesity that obesity could be a significant independent predictor of unfavorable disease-free and overall survival among patients with colorectal cancer of reduced NDRG4 expression, but not among those with preserved NDRG4. These findings may have considerable clinical implications in obesity associated colorectal cancer management.

MATERIALS AND METHODS {#s4}
=====================

Patients and specimens {#s4_1}
----------------------

This study was approved by the ethics committee of the Fourth Military Medical University. All patients involved provided full consent for the present study. The hospital-based study cohort including 226 patients consecutively diagnosed with colorectal cancer between January 2004 and December 2005 in Department of Gastrointestinal Surgery, Xijing Hospital, Fourth Military Medical University (Xi\'an, China). Priori power calculation was not performed and the sample size was determined by access to a convenience sample of patients. Patients with following criteria were subsequently excluded: received treatment prior to surgery including neoadjuvant chemotherapy; harvested insufficient specimens for RNA isolation; diagnosed as gastrointestinal stromal tumor or lymphoma; diagnosed with additional cancers; refused consent. Clinicopathologic information and follow-up data of the remaining 226 patients were prospectively entered into a database, which was under a close follow-up scheme and updated with respect to survival status every three month by telephone visit and questionnaire letters. Thirty-six noncancerous healthy colon mucosa tissues obtained from patients underwent surgery or endoscopy without malignancy served as control. All the fresh tissues were obtained within 10 minutes after surgical removal and put into liquid nitrogen for 10 min, then into a −80°C ultra-freezer for mRNA isolation. All the specimens had been histologically diagnosed by Department of Pathology, Xijing Hospital, Fourth Military Medical University. Study physicians who reviewed all the records of colorectal cancer and recorded data into database were totally blind to exposure data. Clinicopathologic information of all the 226 patients was available.

Measurement of endpoints {#s4_2}
------------------------

In the present study, disease-free survival is defined as the time elapsed from surgery to the first occurrence of any of the following events: colorectal cancer distant metastasis; recurrence of colorectal cancer; development of second non-colorectal malignancy excluding basal cell carcinomas of the skin and carcinoma *in situ* of the cervix; or death from any cause. The diagnosis of disease relapse was based on the imaging method such as ultrasonography, computed tomography, magnetic resonance imaging and position emission tomography, if possible, cytologic analysis or biopsy. Overall survival is defined as the time elapsed from surgery to death of patients with colorectal cancer. Death of participants was ascertained by reporting from the family and verified by review of public records. The disease-free and overall survival status was assigned by physicians blinded to other clinicopathologic and NDRG4 mRNA expression information.

Assessment of body mass index and smoking status {#s4_3}
------------------------------------------------

To insure the consistency of body mass index (BMI), weight (kilograms) and height (meters) of patients were measured and recorded at uniform time points relative to diagnosis and surgery by trained staff. These measurements were then transferred to trained personnel to calculate BMI by taking the body weight in kilograms divided by height in meters squared. For the present study, participants with BMI less than 18.5 kg/m^2^ had been defined as underweight and excluded, other participants were then categorized according to the World Health Organization (WHO) classification for Asian populations, normal weight (18.5 kg/m^2^ ≤ BMI \< 23.0 kg/m^2^), overweight (23.0 kg/m^2^ ≤ BMI \< 27.5 kg/m^2^) and obese (BMI ≥ 27.5 kg/m^2^).

RNA extraction and real-time polymerase chain reaction {#s4_4}
------------------------------------------------------

When patients recruitment accomplished, total RNA from all the 226 colorectal cancer tissue and matched adjacent normal tissue specimens together with 36 noncancerous healthy colon mucosa tissues was purified as recommended by the manufacturer using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA synthesis was performed using approximately 5 μg RNA per 20 μL using a cDNA reverse transcription kit (Fermentas). Real-time PCR was performed on an ABI 7500 system (Applied Biosystems) using SYBR Green I (TAKARA). Primers were designed using Primer Express v3.0 Software. NDRG4 primers were: forward 5′-GGAGGTTGTCTCTTTGGTCAAGGT-3′, reverse 5′-CTCATGACAGCAGCCACCAGAAT -3′. The internal control 18S rRNA primers were: forward 5′- CGCCGCTAGAGGTGAAATTC -3′ and reverse 5′- TTGGCAAATGCTTTCGCTC -3′. After first strand synthesis, an equivalent of 50 ng of starting total cellular RNA (1/10 of the cDNA reaction) was added to two duplicate PCR reactions containing 12.5 μL SybrGreen mix, 0.5 μL SybrGreen rox, 100 nmol/L forward primer, and 100 nmol/L reverse primer in a final volume of 25 μL. Each sample was used in a single reaction that cycled at 95°C for 10 min (to activate enzyme), followed by 45 cycles of 95°C for 10 s and 60°C for 34 s on an ABI SDS 7500 system (Applied Biosystems). The mRNA expression of NDRG4 was analyzed using the 2^−ΔΔCt^ method. Fluorescent data were converted into RQ measurements, which stand for relative expression automatically by the SDS system software and exported to Microsoft Excel. NDRG4 mRNA levels were normalized to 18S rRNA. Thermal dissociation plots were examined for biphasic melting curves, indicative of whether primer-dimers or other nonspecific products could be contributing to the amplification signal. Sequencing of randomly selected real-time PCR product was utilized to insure the quality of real-time PCR.

DNA extraction, microsatellite instability (MSI), pyrosequencing of KRAS, BRAF and PIK3CA analysis {#s4_5}
--------------------------------------------------------------------------------------------------

MSI status was determined via testing on a 10-gene panel in tumor DNA using 10 microsatellite markers (BAT25, BAT26, BAT40, MYCL, D5S346, D17S250, ACTC, D18S55, D10S197, and BAT34C4) as described in previous study \[[@R56]\]. In brief, tumors with MSI-high/ microsatellite stability (MSI-H) was defined if instability was observed for ≥ 30% of markers, while and MSI-low/microsatellite stability (MSS) was defined if instability was observed for \< 30% of the markers. And we also performed PCR and pyrosequencing targeted for KRAS (codons 12 and 13), BRAF (codon 600) and PIK3CA (exons 9 and 20) \[[@R57]--[@R59]\].

Statistical analysis {#s4_6}
--------------------

Statistical analysis was carried out by the statistical package SPSS (version l3.0). Associations between NDRG4 mRNA expression and categorical variables were analyzed by Pearson *χ*^2^ test or Fisher\'s exact test, as appropriate. Survival curves were estimated using the Kaplan-Meier method, and differences in survival distributions were evaluated by the log-rank test. Cox\'s proportional hazards modeling of factors potentially related to survival was performed in order to identify which factors might have a significantly independent influence on survival. Differences with a *P* value of 0.05 or less were considered to be statistically significant.
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